Acrivon公布2026年第一季度财务业绩,并强调实现2026年关键临床里程碑的进展

美股速递
May 14

Acrivon Therapeutics, Inc.发布了其2026年第一季度的财务报告,同时重点介绍了公司在推进2026年关键临床催化剂方面取得的显著进展。报告期内,公司持续推进其核心研发管线的开发工作,为达成年度重要临床目标奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10